Revenue Showdown: Corcept Therapeutics Incorporated vs PTC Therapeutics, Inc.

Biotech Giants' Revenue Battle: Corcept vs. PTC

__timestampCorcept Therapeutics IncorporatedPTC Therapeutics, Inc.
Wednesday, January 1, 20142655100022963000
Thursday, January 1, 20155028600036766000
Friday, January 1, 20168132100082705000
Sunday, January 1, 2017159201000194392000
Monday, January 1, 2018251247000264734000
Tuesday, January 1, 2019306486000306980000
Wednesday, January 1, 2020353874000380766000
Friday, January 1, 2021365978000538593000
Saturday, January 1, 2022401858000698801000
Sunday, January 1, 2023482375000937822000
Loading chart...

Unleashing the power of data

Revenue Showdown: A Tale of Two Therapeutics

In the competitive landscape of biotechnology, Corcept Therapeutics Incorporated and PTC Therapeutics, Inc. have been vying for dominance over the past decade. Since 2014, both companies have shown remarkable growth in revenue, with PTC Therapeutics taking a commanding lead by 2023.

A Decade of Growth

Corcept Therapeutics started with a modest revenue in 2014, but by 2023, it had increased its revenue by nearly 1,700%, showcasing a steady upward trajectory. Meanwhile, PTC Therapeutics, which began with a similar revenue base, surged ahead with an impressive 4,000% growth over the same period.

The Competitive Edge

By 2023, PTC Therapeutics' revenue was almost double that of Corcept, highlighting its aggressive expansion and market penetration. This revenue showdown underscores the dynamic nature of the biotech industry, where innovation and strategic investments can lead to exponential growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025